• Apogee Therapeutics Inc APGE.OQ reported a quarterly adjusted loss of 95 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -64 cents. The mean expectation of eight analysts for the quarter was for a loss of $1.25 per share. Wall Street expected results to range from $-1.65 to $-1.13 per share.

• Reported revenue was zero​; analysts expected zero.

• Apogee Therapeutics Inc's reported EPS for the quarter was a loss of 95 cents​.

• The company reported a quarterly loss of $55.34 million.

• Apogee Therapeutics Inc shares had fallen by 0.2% this quarter and lost 17.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 21.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

• Wall Street's median 12-month price target for Apogee Therapeutics Inc is $90.00

This summary was machine generated from LSEG data May 12 at 05:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)